Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Sellas Life Sciences Group (SLS) · oqro.io/stocks/SLS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Sellas Life Sciences Group insider trading
Have Sellas Life Sciences Group insiders bought shares recently?
No open-market purchase by an insider of Sellas Life Sciences Group was filed in the last 90 days. The latest on record was on Jun 13, 2025.
How often do Sellas Life Sciences Group insiders buy and sell shares?
Since 2009, Sellas Life Sciences Group insiders reported 8 open-market purchases and 115 sales on Forms 4 and 5, with purchases in 4 different years, most recently 2025.
Who is selling Sellas Life Sciences Group stock?
No open-market sale by an insider of Sellas Life Sciences Group (SLS) was filed with the SEC in the last 90 days.
Do members of Congress trade SLS?
No trade in Sellas Life Sciences Group (SLS) was disclosed by a member of Congress in the last 12 months.
When does Sellas Life Sciences Group report its next results?
Sellas Life Sciences Group's next results are expected on Mar 17, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+877.6% (+$13.34) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
Adjusted close went from $1.52 on Nov 19, 2025 to $14.86 on Nov 19, 2026 (+877.6%). Disclosed in this range: 0 insider trades, 3 pre-arranged insider sales, 0 Congress trades, and 1 13F position change for 1 quarter ending in it.
$-5$0$5$10$20$25$14.86
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 3 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in New York, Ny.
Last 12 months
+877.6%
S&P 500 +8.0% over the same dates
Market value
$3.03B
Close of Nov 19, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 57.1M shares sold short (28.0% of shares outstanding), +6.3% vs the previous count, 6.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Latest results: quarter ending Sep 30, 2026
Revenue
$0
Year earlier: $0
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $135M, at Sep 30, 2026
Net income, last 12 months
−$35.8M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
3 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Since the trade +800.6% · S&P 500 +18.6% · to Nov 19
A Sellas Life Sciences director paid $15K out of pocket for Sellas Life Sciences shares. 2 other people at Sellas Life Sciences bought some too, in the same month. Shares held went up 96% with this purchase.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
When insiders usually buy
Last results
Nov 12, 2026
Within the 30 days after it, until Dec 12, 2026
Next results, expected
Mar 17, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Sellas Life Sciences Group's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Sellas Life Sciences Group's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Insider buying and selling since 2009
Insiders of Sellas Life Sciences Group reported 8 open-market purchases and 115 sales since 2009; purchases in 4 different years, most recently 2025.
Year
Bought
Sold
2025
$85K3×3 trades
—
2022
—
$26K3×3 trades
2021
—
$20K3×3 trades
2018
—
$29K1×1 trade
2017
—
$1.99M2×2 trades
2016
—
$277K1×1 trade
2014
$99K1×1 trade
$16.1M13×13 trades
2011
$19K3×3 trades
—
2010
$22K1×1 trade
$16.2M8×8 trades
2009
—
$2.18M84×84 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Late-stage clinical trials
1 active phase 3 trial and 1 active phase 2 trial led by this company, mostly in acute myeloid leukemia, hematologic malignancies. The ones with the nearest registered primary completion date still ahead:
1 trial has a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
On the public record for Sellas Life Sciences Group over the 12 months to Nov 21, 2026: 1 clinical trial.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Sellas Life Sciences Group filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions. In the 12 months before that, they filed 3 open-market purchases (about $85K, in 3 filings) and 0 open-market sales (about $0, in 0 filings). (Sellas Life Sciences Group on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 1 new or larger position and 0 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. ClinicalTrials.gov shows 1 study sponsored by the company updated in the period; the latest, "Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malig..." (Phase 2, status recruiting), was updated on Sep 3, 2026, with primary completion listed for 2026-12-30. FINRA short interest for SLS on the settlement date of Oct 30, 2026 was 57,126,298 shares (+6.26% on the previous report), about 6.7 days of average volume.
Company reports, price and press. Sellas Life Sciences Group filed a Form 8-K on Nov 12, 2026 (Item 2.02) that OQRO classes as: reported its results. Sellas Life Sciences Group filed a Form 8-K on Aug 11, 2026 (Item 2.02) that OQRO classes as: reported its results.
Who holds it. 190 funds reported a stake in Sellas Life Sciences Group in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (20.6% of the value reported), STATE STREET CORP (17.8% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (11.3% of the value reported).
Attention. The English Wikipedia article on Sellas Life Sciences Group was read about 13 times a day in the 7 days to Nov 18, 2026, against a usual 4 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Sellas Life Sciences Group filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 3 open-market purchases (about $85K, in 3 filings) and 0 open-market sales (about $0, in 0 filings).
Funds and stakes
Fund 13F filings recorded in the 12 months show 1 new or larger position and 0 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
ClinicalTrials.gov shows 1 study sponsored by the company updated in the period; the latest, "Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malig..." (Phase 2, status recruiting), was updated on Sep 3, 2026, with primary completion listed for 2026-12-30.
FINRA short interest for SLS on the settlement date of Oct 30, 2026 was 57,126,298 shares (+6.26% on the previous report), about 6.7 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Perceptive Advisors LLC (new position); Orbimed Advisors LLC (new position); the largest that shrank: Farallon Capital Management, L.L.C. (sold out). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $1.88M for its principal executive officer, and an average of $976K for the other named executive officers.
Company reports, price and press
Sellas Life Sciences Group filed a Form 8-K on Nov 12, 2026 (Item 2.02) that OQRO classes as: reported its results.
Sellas Life Sciences Group filed a Form 8-K on Aug 11, 2026 (Item 2.02) that OQRO classes as: reported its results.
Sellas Life Sciences Group filed a Form 8-K on Jun 25, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On June 24, 2026, SELLAS Life Sciences Group, Inc. (the 'Company') entered into (i) an amendment (the 'Stergiou Amendment') to that certain employment agreement effective as of July 1, 2019 (the 'Stergiou Employment Agreement'),..."
Press coverage listed by Finnhub: "Stock Futures Climb Ahead Of Anthropic's Nasdaq Debut, NVDA, BABA, TTWO, SLS Stocks In Focus" (Yahoo, Nov 19, 2026).
Press coverage listed by Finnhub: "NetEase Downbeat Q3 Results, Joins Red Robin, Sellas Life Sciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session" (Benzinga, Nov 19, 2026).
Press coverage listed by Finnhub: "SLS Stock Plunges Overnight As Sellas’ Discounted Share Offering Has Retail Bulls Crying Foul: ‘Crazy Low Price’" (Yahoo, Nov 19, 2026).
SLS closed at $17.95 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $10.49 to $17.95, a change of +71.1%.
Who holds it
190 funds reported a stake in Sellas Life Sciences Group in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (20.6% of the value reported), STATE STREET CORP (17.8% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (11.3% of the value reported).
Attention
The English Wikipedia article on Sellas Life Sciences Group was read about 13 times a day in the 7 days to Nov 18, 2026, against a usual 4 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
People read Sellas Life Sciences Group's Wikipedia article about 14 times a day over the last week, 3.5 times the 4 on a usual day of the three months before.
May 15, 2026Busiest day: 43 views on Nov 17, 2026Nov 19, 2026
Views of the article Galena Biopharma, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
Fails to deliver: 108K shares (about $1.09M) were not delivered on time for settlement on Oct 30, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 50.5% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (13.0% on ATS, 37.5% with other brokers), below its 26-week average of 53.6%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: INTELLIGENT CROSS LLC (12.5%), UBS ATS (11.8%), SIGMA X2 (8.7%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
From “Overview”, in the company's words
We are a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and SLS009 (formerly GFH009), a highly selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
What the section covers (26 headings)
Overview
Galinpepimut-S, or GPS: Highly Novel and Engineered Immunotherapy Targeting the WT1 Antigen
SLS009, or Tambiciclib: Highly Selective Next Generation CDK9 Inhibitor
Components of Results of Operations
Research and Development
General and Administrative Expense
Non-Operating Income
Results of Operations for the Years Ended December 31, 2025 and 2024
General and Administrative
Liquidity and Capital Resources
Sources of Liquidity
Funding Requirements
Components of Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Cash Flows
And 12 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 19, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Risk factors in the annual report
Latest annual report filed Mar 19, 2026, compared with the one filed Mar 20, 2025. Read the filing
No longer listed (1 heading from the year before)
Our cash and cash equivalents balance as of December 31, 2024 will fund our operations for less than one year.
Legal proceedings (Item 3)
In December 2020, we entered into 3D Medicines Agreement. In November 2022, we announced that we had agreed with 3D Medicines for 3D Medicines to participate in the REGAL study through the inclusion of approximately 20 patients from mainland China. In accordance with the terms of the 3D Medicines Agreement and the Side Letter, we had expected that 3D Medicines would begin enrolling patients in mainland China in the REGAL study in the second half of 2023 and subsequently make two development milestone payments totaling $13.0 million.
Source: SEC EDGAR, Form 10-K filed Mar 19, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
1 certified in FY2026 Q3, vs 0 a year earlier. 1 position in total, median offered wage $235K a year.
Senior Director Regulatory Affairs · 1
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.